Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 2

1(16.7%)

Phase 3

1(16.7%)

6Total

N/A(4)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02240472Not ApplicableActive Not Recruiting

Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.

Role: collaborator

NCT05572801Not ApplicableRecruiting

NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer

Role: collaborator

NCT02473003Not ApplicableUnknown

Physical Training and Cancer-a Multicenter Clinical Trial

Role: collaborator

NCT01458730Phase 2Completed

Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Role: collaborator

NCT00225641Not ApplicableUnknown

Assessment of Frequency of Surveillance After Curative Resection in Patients With Stage II and III Colorectal Cancer

Role: collaborator

NCT00376883Phase 3Completed

Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

Role: collaborator

All 6 trials loaded